Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | ABL1 | P00519 | 9/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | IGF1R | P08069 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2914329 | 0.87 | TRPV1 (0.74) | TRPV1HTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL29687568 | 0.85 | ABL1 (0.70) | ABL1 | |
| SCHEMBL23091712 | 0.85 | ABL1 (0.70) | ABL1 | |
| SCHEMBL22815834 | 0.81 | TRPV1 (0.76) | TRPV1HTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL30159339 | 0.80 | ABL1 (0.51) | ABL1 | |
| SCHEMBL24849953 | 0.80 | ABL1 (0.51) | ABL1 | |
| SCHEMBL15391645 | 0.79 | ABL1 (0.71) | TRPV1HTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL15390862 | 0.78 | ABL1 (0.69) | TRPV1HTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL17448399 | 0.78 | SMN1; SMN2 (0.71) | TRPV1HTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL6657635 | 0.78 | TRPV1 (0.76) | TRPV1HTTSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002346-A1 | NEW COMPOUNDS AND METHODS | BenevolentAl Bio Limited (GB) | 2023-01-05 | — | — | US | disclosed |
| US-20230002346-A1 | NEW COMPOUNDS AND METHODS | BenevolentAl Bio Limited (GB) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002346-A1 | NEW COMPOUNDS AND METHODS | ABL2, ABL1, ALK | TRPV1 1085/4885HTT 2332/4885SMN1; SMN2 2246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.